Anti SEZ6 antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-9676850-B2
Application number	US-201314380665-A
Country	US
Kind code	B2
Filing date	Feb 22, 2013
Priority date	Feb 24, 2012
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. An isolated antibody or fragment thereof of, that specifically binds a human seizure related 6 homolog (SEZ6) protein, wherein said antibody or fragment thereof comprises:
(a) three CDRs of a light chain variable region of SEQ ID NO: 44 and three CDRs of a heavy chain variable region of SEQ ID NO: 45;
(b) three CDRs of a light chain variable region of SEQ ID NO: 48 and three CDRs of a heavy chain variable region of SEQ ID NO: 49;
(c) three CDRs of a light chain variable region of SEQ ID NO: 64 and three CDRs of a heavy chain variable region of SEQ ID NO: 65;
(d) three CDRs of a light chain variable region of SEQ ID NO: 68 and three CDRs of a heavy chain variable region of SEQ ID NO: 69;
(e) three CDRs of a light chain variable region of SEQ ID NO: 80 and three CDRs of a heavy chain variable region of SEQ ID NO: 81;
(f) three CDRs of a light chain variable region of SEQ ID NO: 116 and three CDRs of a heavy chain variable region of SEQ ID NO: 117;
(g) three CDRs of a light chain variable region of SEQ ID NO: 122 and three CDRs of a heavy chain variable region of SEQ ID NO: 123;
(h) three CDRs of a light chain variable region of SEQ ID NO: 130 and three CDRs of a heavy chain variable region of SEQ ID NO: 131;
(i) three CDRs of a light chain variable region of SEQ ID NO: 134 and three CDRs of a heavy chain variable region of SEQ ID NO: 135;
(j) three CDRs of a light chain variable region of SEQ ID NO: 138 and three CDRs of a heavy chain variable region of SEQ ID NO: 139;
(k) three CDRs of a light chain variable region of SEQ ID NO: 146 and three CDRs of a heavy chain variable region of SEQ ID NO: 147;
(I) three CDRs of a light chain variable region of SEQ ID NO: 150 and three CDRs of a heavy chain variable region of SEQ ID NO: 151;
(m) three CDRs of a light chain variable region of SEQ ID NO: 154 and three CDRs of a heavy chain variable region of SEQ ID NO: 155;
(n) three CDRs of a light chain variable region of SEQ ID NO: 158 and three CDRs of a heavy chain variable region of SEQ ID NO: 159;
(o) three CDRs of a light chain variable region of SEQ ID NO: 160 and three CDRs of a heavy chain variable region of SEQ ID NO: 161;
(p) three CDRs of a light chain variable region of SEQ ID NO: 162 and three CDRs of a heavy chain variable region of SEQ ID NO: 163;
(q) three CDRs of a light chain variable region of SEQ ID NO: 164 and three CDRs of a heavy chain variable region of SEQ ID NO: 165; and
(r) three CDRs of a light chain variable region of SEQ ID NO: 168 and three CDRs of a heavy chain variable region of SEQ ID NO: 169.

2. The antibody or fragment thereof of claim 1 comprising a V L and a V H , wherein the V L has three complementarity determining regions of SEQ ID NO: 168, and the V H has three complementarity determining regions of SEQ ID NO: 169.

3. The antibody or fragment thereof of claim 2 comprising residues 24-34 of SEQ ID NO: 168 for CDR-L1, residues 50-56 of SEQ ID NO: 168 for CDR-L2, residues 89-97 of SEQ ID NO: 168 for CDR-L3, residues 31-35 of SEQ ID NO: 169 for CDR-H1, residues 50-65 of SEQ ID NO: 169 for CDR-H2 and residues 95-102 of SEQ ID NO: 169 for CDR-H3, wherein the residues are numbered according to Kabat.

4. The antibody or fragment thereof of claim 2 , wherein the V L comprises SEQ ID NO: 190 and wherein the V H comprises SEQ ID NO: 191.

5. The isolated antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a monoclonal antibody.

6. The isolated antibody or fragment thereof of claim 5 , wherein the monoclonal antibody is selected from the group consisting of chimeric antibodies, humanized antibodies and human antibodies.

7. The isolated antibody or fragment thereof of claim 1 , wherein said antibody is conjugated to a cytotoxic agent.

8. The isolated antibody or fragment thereof of claim 7 , wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD).

9. The isolated antibody or fragment thereof of claim 7 , wherein the cytotoxic agent comprises an auristatin.

10. The isolated antibody or fragment thereof of claim 7 , wherein the cytotoxic agent comprises a maytansinoid.

11. The isolated antibody or fragment thereof of claim 7 , wherein the cytotoxic agent comprises a calicheamicin.

12. The isolated antibody or fragment thereof of claim 7 , wherein the cytotoxic agent comprises a radioisotope.

Assignees

• Stem Centrx Inc
• Abbvie Stemcentrx Llc

Inventors

• Saunders Laura
• Dylla Scott J
• Foord Orit
• Stull Robert A
• Torgov Michael
• Shao Hui
• Liu David

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title